Med-tech company Volpara (ASX:VHT) today released their quarter cash flow report for the period ending September 30, and once again managed to post some encouraging figures.
Cash receipts from customers grew a solid 190% from the same quarter last year, coming in at NZ$4.9 million. Despite the gain, Volpara is still not generating a positive operating cash flow, with net operating cash outflows of NZ$4.2 million for the quarter, or NZ$7.2 million for the first half.
The group’s cash position did, however, improve by a small amount, coming in at NZ$40.2 million thanks to the fresh injection of capital from retail shareholders during the quarter. Volpara also said that despite a deterioration in operating cash flows — due mostly to the timing of a payroll adjustment — that costs were running at or below budget.
Group annual recurring revenue (ARR) — an all important metric for SaaS companies — improved by NZ$1 million, or roughly 7%, over the latest quarter. The company was pleased with this given that the second quarter is traditionally the weakest, and said the business remained on track to meet its mid-range forecast of NZ$17.1 million for the full year. Further, with an estimated 25.8% of screened US women using at least one one of Volpara’s products, the company was also on track to meet the full year target of 27% of US women having a group product applied to their images and data.
The average revenue per user (ARPU) generated across breast cancer operations also showed a slight uptick, rising from NZ$1.37 million to NZ$1.41 million. Once the full suite of products converts to a SaaS model (likely in the next month), management expect to see a solid uptick in this metric.
Ranked #13 on Strawman, shares in Volpara remain below the community consensus valuation. Click below to uncover insights from some of Australia’s best private investors.
Strawman is Australia’s premier online investment club. Join for free to access independent & actionable recommendations from proven private investors.
Disclaimer– The author may hold positions in the stocks mentioned in this publication, at the time of writing. The information contained in the publication and the links shared are general in nature and does not take into account your personal situation. You should consider whether the information is appropriate to your needs, and where appropriate, seek professional advice from a financial adviser. For errors that warrant correction please contact the editor at [email protected]
© 2019 Strawman Pty Ltd. All rights reserved.
ACN: 610 908 211 | Australian Financial Services Licence (AFSL): 501223